Successful Management of Hemodynamically Unstable Takotsubo Cardiomyopathy With Milrinone

Karan H. Pahuja, Natale Wasef, Syed Hasan, Tehreem Fatima, Steven Hamilton, Marc Seelagy

Abstract

Takotsubo cardiomyopathy (TTC) was initially reported in the 1990s as a reversible cause of cardiomyopathy induced by acute emotional stress. It is characterized by regional systolic dysfunction in the absence of coronary artery disease. We report a case of a 79-year-old woman who was admitted with acute respiratory failure due to pneumonia and was found to have a troponin elevation. Upon further evaluation, the patient was taken to the cardiac catheterization lab and underwent catheterization which showed apical ballooning concerning Takotsubo cardiomyopathy. She was placed on a norepinephrine drip but remained unstable. Milrinone-facilitated diuresis was then initiated with improvement and stabilization in hemodynamics. Takotsubo cardiomyopathy presenting with cardiogenic shock without left ventricular outflow tract obstruction requires treatment with inotropes. Although there is limited data to support the use of milrinone in cardiogenic shock due to TTC, its use in our case facilitated diuresis and improved the patient’s outcome after norepinephrine failed to stabilize our patient’s hemodynamics. Milrinone inhibits phosphodiesterase type 3 which increases the calcium influx thereby improving the myocardial contraction without any beta agonist action. Therefore, the use of milrinone which is a non-catecholamine inotrope could be considered a better alternative as compared to dobutamine given the underlying pathophysiology of TTC.

Introduction

Takotsubo cardiomyopathy (TTC) was first reported in the 1990s by Japanese authors. It is reversible cardiomyopathy that is precipitated by acute emotional stress. TTC is characterized by transient regional systolic dysfunction of the left ventricle in the absence of coronary artery disease or acute plaque rupture. In most Takotsubo cardiomyopathy cases, a large area of the heart wall is involved, which is perfused by multiple coronary arteries [1]. TTC is also known as transient apical ballooning syndrome, stress-induced cardiomyopathy, stress cardiomyopathy, and broken-heart syndrome. It is much more common in women than men and occurs predominantly in older individuals [2]. Various hypotheses have been proposed to understand the possible pathophysiological mechanisms. The catecholamine hypothesis is widely accepted. According to this hypothesis, stress, estrogen deficiency, microvascular dysfunction, or microcirculatory disorder could lead to disproportionate catecholamine secretion, which can stun the myocardium [3]. There is no data available regarding ideal treatment of Takotsubo cardiomyopathy, but therapy is guided by the patient’s clinical presentation and hemodynamic status. In stable patients, treatment modalities include cardio-selective beta-blockers and angiotensin-converting enzyme (ACE) inhibitors. Patients with unstable hemodynamics (hypotension) may be treated with inotropes [4]. Here, we present a case of Takotsubo cardiomyopathy that was successfully treated with milrinone.

This article was previously presented as a poster abstract at the 2021 American College of Cardiology (ACC) Latin America Conference on November 5, 2021.

Case Presentation

A 79-year-old woman was brought to our emergency department after being intubated in the field by the EMS due to worsening shortness of breath and productive cough that started earlier that day. The nasotracheal route was used after failed attempts at the oropharyngeal route.

Her past medical history was significant for coronary artery disease (CAD) status post three drug-eluting stents and heart failure with mid-range ejection fraction (HFmrEF) with ejection fraction (EF) 40-45%, systemic hypertension, prediabetes, obesity, and gastroesophageal reflux disease (GERD). On examination, the patient had 1+ bilateral lower extremity pitting edema, predominantly right-sided rhonchi, without prominent jugular venous distension (JVD) or a third heart sound (S3). Laboratory values are shown in Table 1.
## Test Results

| Test                     | Results | Reference | Unit   |
|-------------------------|---------|-----------|--------|
| pH                      | 7.15    | 7.35-7.45 | -      |
| Arterial PaCO₂          | 91.3    | 35-45     | mmHg   |
| Arterial bicarbonate    | 33.8    | 22-26     | mmol/L |
| BNP                     | 750     | <100      | pg/mL  |
| Creatinine              | 1.2     | 0.49-1.01 | mg/dL  |
| BUN                     | 22      | 7-25      | mg/dL  |
| Lactate                 | 2.8     | 0.5-2.0   | mmol/L |
| WBC count               | 10.9    | 3.8-10.2  | 10^3/μL|
| Neutrophil count        | 61      | 42.7-76.7 | %      |
| COVID-19 RT-PCR test    | Negative| Negative  | -      |

### TABLE 1: Laboratory values of the patient

PaCO₂: partial pressure of carbon dioxide; BNP: brain natriuretic peptide; BUN: blood urea nitrogen; WBC: white blood cell; RT-PCR: reverse transcriptase polymerase chain reaction

Chest x-ray (CXR) demonstrated bilateral, right greater than left, opacities, and left costophrenic angle blunting which was suggestive of pulmonary edema and/or pneumonia. She received a one-time dose of furosemide 60mg intravenously (IV) with minimal urine output. Additionally, she was initiated on ceftriaxone, azithromycin, and metronidazole.

She required minimal settings on the ventilator, however, failed a spontaneous breathing trial on day 2 due to tachypnea. Over the next two days, her ventilator requirements increased from a positive end-expiratory pressure (PEEP) of 5 to a PEEP of 10. Additionally, the patient went into new-onset atrial fibrillation with controlled ventricular response (CVR) and was subsequently started on IV unfractionated heparin.

Spontaneous breathing trial was successful on day 5 of admission and she was extubated via her nasopharyngeal passage. Upon extubation, the patient was noted to have significant epistaxis. Her IV unfractionated heparin was immediately discontinued and the nasal passage was packed with epinephrine-soaked gauze. Subsequently, she endorsed a sense of doom and severe substernal chest pain. Electrocardiogram (EKG) showed atrial fibrillation with CVR and chronic left bundle branch block (Figure 1).
FIGURE 1: EKG showing atrial fibrillation with controlled ventricular response during the stress-induced cardiomyopathy event

Blue arrows showing the left bundle branch block and orange arrows showing the irregular rhythm and absent p-wave consistent with atrial fibrillation.

Troponin level was 2.4 ng/mL, increased from 0.06 ng/mL on admission and she became increasingly tachypneic requiring reintubation via the orotracheal route. Immediate cardiac catheterization revealed apical and mid segments akinesia with normokinetic basal segments consistent with Takotsubo cardiomyopathy (Figures 2A, 2B).

FIGURE 2: Invasive coronary angiogram demonstrating Takotsubo pattern

(A) Systole - red arrow showing apical akinesia and black arrows showing normokinetic basal segment; (B) diastole - black arrows showing normokinetic basal segment.

There was mild non-obstructive CAD with patent stents and left ventricular (LV) end-diastolic pressure of 16 mmHg. Additionally, a transthoracic echocardiogram revealed severely reduced left ventricular systolic function, EF 20–25%, an aneurysmal LV anterior wall and multiple wall motion abnormalities, and no LV outflow tract obstruction. The patient was started on IV amiodarone after which she converted to sinus rhythm and was restarted on IV unfractionated heparin since her hemoglobin remained stable and there was no recurrence of the epistaxis. Within 24 hours, there were multiple episodes of hypotension and vascular congestion on chest x-ray, which required the use of norepinephrine, with hemodynamics remaining labile (Figure 3).
FIGURE 3: Chest x-ray showing with the black arrows showing vascular congestion/pulmonary edema

On day 11, she was successfully extubated again to room air and remained comfortable throughout the day. Unfortunately, she became tachypneic and restless overnight, requiring reintubation for the third time. After the patient’s third reintubation, her blood pressure remained labile to the point where the furosemide had to be held, however, the following day her central venous pressure (CVP) increased to 23 mmHg. Since diuresis was limited due to persistent hypotension, milrinone-assisted diuresis was initiated at 0.25 mcg/kg/min. After three days of milrinone-assisted diuresis, the patient was aggressively diuresed with furosemide 40 mg IV twice daily to euvolemia with hemodynamic stability. On day 19 of admission, the patient was successfully extubated to bi-level positive airway pressure. Her oxygen requirements decreased over the next few days and the milrinone was eventually discontinued. The patient did well off the milrinone and was maintained on oral diuretics and nasal cannula until discharge. She will have a repeat transthoracic echocardiogram in 90 days.

Discussion

Patients with Takotsubo cardiomyopathy (TTC) presenting with cardiogenic shock without left ventricular outflow tract obstruction require treatment with inotropes. Cardiogenic shock is most frequently treated with dobutamine or epinephrine \[5,6\]. However, there is little data available on the use of milrinone in the case of cardiogenic shock due to TTC.

There is no optimal medical regimen for stress-induced cardiomyopathy. The driving pathophysiology is disproportionate catecholamine release leading to direct myocardial injury and stunning. Although it is a transient disorder that requires supportive therapy, some patients like ours develop acute complications like shock and acute heart failure. Given that TTC is related to disproportionate catecholamine release which consequently stuns the myocardium, use of milrinone, a non-catecholamine inotrope is a reasonable option instead of catecholamine inotropes \[7\].

Takotsubo cardiomyopathy with hypotension and heart failure is an ICU dilemma for which the treatment is debatable. Catecholamine inpressors such as norepinephrine may cause paradoxical beta receptor negative inotropic effects, necessitating the use of milrinone. Milrinone inhibits phosphodiesterase type 3 and increases the calcium influx thereby improving the myocardial contraction without any beta agonist action \[8\]. There is also an added advantage of less increase in the heart rate and myocardial oxygen demand as
compared to dobutamine. However, it may cause hypotension due to peripheral vasodilation [8].

Very few cases have been reported regarding the use of milrinone in cases of cardiogenic shock due to TTC. In our case, milrinone was chosen considering the underlying pathophysiology of TTC and the risk of arrhythmias with dobutamine given that this patient had new-onset atrial fibrillation during hospitalization. Doyen et al. reported one of the initial cases of TTC where lactate levels and cardiac index improved only after starting milrinone infusion [7]. Mrozek et al. also reported a case where dobutamine infusion was discontinued in TTC due to tachyarrhythmia followed by milrinone which stabilized the patient’s hemodynamic status and improved cardiac output without deleterious effects [9]. Milrinone has also shown benefits in acute right heart failure due to isolated right ventricular Takotsubo syndrome [10]. To further support the use of a non-catecholamine inotrope, dobutamine infusion is known to trigger TTC [11,12]. Another non-catecholamine inotrope such as levosimendan has also shown successful outcomes in the treatment of TTC [13]. However, it is not commonly used given the increased risk of vasoplegia and hypotension [14]. The recent Dobutamine Compared with Milrinone (DOREMI) trial showed that, among patients with cardiogenic shock, there were no significant differences in cardiovascular or renal outcomes between intravenous milrinone and dobutamine [15]. However, when it comes to cardiogenic shock due to Takotsubo cardiomyopathy the use of a non-catecholamine inotrope like milrinone could be considered a better alternative as compared to dobutamine given the underlying pathophysiology of TTC.

**Conclusions**

Takotsubo cardiomyopathy with hypotension and heart failure is an ICU dilemma. Catecholamine inopressors may cause negative inotropic effects, necessitating use of milrinone. It provides afterload reduction, positive inotropy, less heart rate increase, and less myocardial oxygen consumption. Ultimately, this facilitates effective diuresis.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Akashi YJ, Nakazawa K, Sacakibara M, Miyake F, Koike H, Sasaki K: The clinical features of Takotsubo cardiomyopathy. JQM. 2005, 96:565-73. 10.1093/qjmed/hcg096
2. Sharkey SW, Lesser JR, Zenoich AG, Maron MS, Lindberg J, Longe TF, Maron BJ: Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005, 111:472-9. 10.1161/CIRCULATIONAHA.104.152950
3. Pelliccia F, Kaski JC, Crea F, Camici PG: Pathophysiology of Takotsubo syndrome. Circulation. 2017, 135:2426-41. 10.1161/CIRCULATIONAHA.116.027121
4. Ahmad S, Brito D, Khalid N, et al.: Takotsubo cardiomyopathy. StatPears [Internet]. StatPears Publishing, Treasure Island, Fl; 2022.
5. Sattar Y, Siew KS, Connerney M, Ullah W, Arai MC: Management of Takotsubo syndrome: a comprehensive review. Cureus. 2020, 12:10.7759/cureus.6556
6. Follath F, Yilmaz MB, Delgado JF, et al.: Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011, 37:619-26. 10.1007/s00134-010-2115-9
7. Doyen D, Dellamonica J, Moceri P, Moschietto S, Hyvernat H, Ferrari E, Bernardin G: Tako-Tsubo cardiomyopathy presenting with cardiogenic shock successfully treated with milrinone: a case report. Heart Lung. 2014, 43:331-5. 10.1016/j.hrtlng.2014.03.007
8. Mager G, Klöcke RK, Kux A, Hopp HW, Hilger HH: Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J. 1991, 121:1974-83. 10.1016/0002-8703(91)90834-5
9. Mrozek S, Skrair M, Marbar F, et al.: Successful treatment of inverted Takotsubo cardiomyopathy after severe traumatic brain injury with milrinone after dobutamine failure. Heart Lung. 2016, 45:406-8. 10.1016/j.hrtlng.2016.06.007
10. Carreras-Mora J, Duran-Cambra A, Vilades-Medel D, et al.: An exceptional cause of acute right heart failure: isolated right ventricular Takotsubo syndrome. JACC Case Rep. 2020, 2:563-9. 10.1016/j.jcacr.2019.10.058
11. Hajesadeghi S, Rabhar MH, Iranspour A, Salehi A, Asadi O, Jafarian SR: Dobutamine-induced Takotsubo cardiomyopathy: a systematic review of the literature and case report. Anatol J Cardiol. 2018, 19:412-6. 10.14744/AnatolJCardiol.2018.78642
12. Mosley WJ 2nd, Manuchehry A, McEvoy C, Rigolin V: Takotsubo cardiomyopathy induced by dobutamine infusion: a new phenomenon or an old disease with a new name. Echocardiography. 2010, 27:30-5. 10.1111/j.1540-8175.2009.01089.x
13. Padayachee L: Levosimendan: the inotrope of choice in cardiogenic shock secondary to Takotsubo
cardiomyopathy. Heart Lung Circ. 2007, 16:65-70. 10.1016/j.hlc.2007.05.018

14. Husebye T, Eritsland J, Müller C, et al.: Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013, 15:565-72. 10.1093/eurjhf/hst215

15. Mathew R, Di Santo P, Jung RG, et al.: Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021, 385:516-25. 10.1056/NEJMoa2026845